Interim CEO Gary S. Stetz buys 1,250,000 shares of HEPA at $0.04; 3 other insiders bought within 14 days
Gary S. Stetz, serving as Interim CEO, purchased 1,250,000 shares at $0.04 on 2026-04-21, representing his first shareholding position in Hepion Pharmaceuticals. This transaction is part of a broader cluster pattern: 3 other insiders also executed purchases within the past 14 days, suggesting coordinated or coincident accumulation activity across the leadership group. The buy occurs at a price substantially below the 52-week high of $0.39, with Hepion currently trading at $0.06 (a level 30% above the transaction price), though the stock remains deeply depressed relative to its year-ago range. The company faces fundamental headwinds: zero revenue in the latest quarter, cumulative net losses of $-472,506.00 in the most recent full fiscal year, and a market capitalization of only $697,219.02, indicating an unprofitable, pre-revenue or minimal-revenue stage biotech. The convergence of multiple insider purchases at a distressed valuation warrants examination of whether this reflects planned capital needs, leadership commitment amid operational stress, or other drivers that should be factored into investment risk assessment.